WO2019071153A1 - PROGRAMMABLE DENDRITIC MEDICINES - Google Patents

PROGRAMMABLE DENDRITIC MEDICINES Download PDF

Info

Publication number
WO2019071153A1
WO2019071153A1 PCT/US2018/054648 US2018054648W WO2019071153A1 WO 2019071153 A1 WO2019071153 A1 WO 2019071153A1 US 2018054648 W US2018054648 W US 2018054648W WO 2019071153 A1 WO2019071153 A1 WO 2019071153A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
occurrence
independently
linker
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/054648
Other languages
English (en)
French (fr)
Inventor
Tracy Matray
Hesham SHERIF
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sony Corp
Sony Corp of America
Original Assignee
Sony Corp
Sony Corp of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sony Corp, Sony Corp of America filed Critical Sony Corp
Priority to EP18792814.8A priority Critical patent/EP3691689A1/en
Priority to JP2020508523A priority patent/JP7403744B2/ja
Priority to KR1020207006070A priority patent/KR20200064059A/ko
Priority to US16/639,499 priority patent/US12290571B2/en
Priority to CN201880056126.7A priority patent/CN111093711A/zh
Publication of WO2019071153A1 publication Critical patent/WO2019071153A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/605—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the macromolecule containing phosphorus in the main chain, e.g. poly-phosphazene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • ADCs Antibody-drug conjugates
  • ADCs are one class of targeted drug conjugates that are of particular interest for cancer treatment.
  • ADCs combine the targeting features of monoclonal antibodies with cancer-killing ability of cytotoxic agents to provide a therapeutic with several advantages over other chemotherapeutics.
  • challenges related to the complexity of ADC constructs, specifically the chemical linker between antibody and drug has caused significant difficulties for development of new and effective therapeutics.
  • Adcetris® and Kadcyla® are commercially available globally (Zevalin® has been approved in China only). Pioneers Pfizer/Wyeth withdrew Mylotarg® in 2010 after safety issues were observed during a comparative clinical trial.
  • isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2 H, 3 H, U C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 0, 31 P, 32 P, 35 S, 18 F, 36 C1, 123 I, and 125 I, respectively.
  • methotrexate platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP- 16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; camptothecin-11 (CPT-11); topoisomeRASe inhibitor RFS 2000;
  • the compounds of the invention are administered in dosages. It is known in the art that due to intersubject variability in compound pharmacokinetics, individualization of dosing regimen is necessary for optimal therapy. Dosing for a compound of the invention may be found by routine experimentation in light of the instant disclosure.
  • compositions optionally include other medicinal or pharmaceutical agents, carriers, adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure, buffers, and/or other therapeutically valuable substances.
  • adjuvants such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure, buffers, and/or other therapeutically valuable substances.
  • poly(methylmethacrylate), polyacrylamide, polycarbophil, acrylic acid/butyl acrylate copolymer, sodium alginate and dextran are examples of poly(methylmethacrylate), polyacrylamide, polycarbophil, acrylic acid/butyl acrylate copolymer, sodium alginate and dextran.
  • Useful pharmaceutical compositions also, optionally, include solubilizing agents to aid in the solubility of a compound of structure (I).
  • solubilizing agent generally includes agents that result in formation of a micellar solution or a true solution of the agent.
  • Certain acceptable nonionic surfactants for example polysorbate 80, are useful as solubilizing agents, as can ophthalmically acceptable glycols, polyglycols, e.g., polyethylene glycol 400, and glycol ethers.
  • useful pharmaceutical compositions optionally include one or more pH adjusting agents or buffering agents, including acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane; and buffers such as citrate/dextrose, sodium bicarbonate and ammonium chloride.
  • acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids
  • bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane
  • buffers such as citrate/dextrose, sodium bicarbonate and ammonium chloride.
  • acids, bases and buffers are included in an amount required to maintain pH of the composition in an acceptable range.
  • cetyltrimethylammonium bromide and cetylpyridinium chloride are examples of cetyltrimethylammonium bromide and cetylpyridinium chloride.
  • lymphoma prostate cancer, rectal cancer, transitional cell cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, stomach (gastric) cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, T-Cell lymphoma, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, transitional cell cancer of the renal pelvis and ureter, trophoblastic tumor, unusual cancers of childhood, urethral cancer, uterine sarcoma, vaginal cancer, vulvar cancer, or Viral-Induced cancer.
  • the analyte molecule is a nucleic acid, amino acid or a polymer thereof (e.g., polynucleotide or polypeptide). In still more embodiments, the analyte molecule is an enzyme, receptor, receptor ligand, antibody, glycoprotein, aptamer or prion.
  • Suitable protecting groups include hydroxy, amino, mercapto and carboxylic acid.
  • Suitable protecting groups for hydroxy include trialkylsilyl or diarylalkylsilyl (for example, t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like.
  • Suitable protecting groups for amino, amidino and guanidino include t-butoxycarbonyl, benzyloxycarbonyl, and the like.
  • Ibuprofen-NHS was reacted with 2-1 (2-amino- 1,3 -propane diol) followed by the addition of a trityl protecting group to afford intermediate 2-3.
  • the protected product 2-3 was then reacted with 2-4 to afford the final product, 2-5 ibuprofen-phosphoramidite (79%).
  • the ibuprofen- phosphoramidite was then used for automated DNA synthesis to incorporate ibuprofen as a representative biologically active moiety into embodiments of the compounds described herein.
  • the composition of the dendrimer backbone can also be selected to afford desirable solubility properties, for example, by controlling the incorporation of charged moieties (e.g., number, frequency, spacing, etc.).
  • the side chains can be selected to provide a source for tuning the solubility of the compounds disclosed herein. For example, providing positively charged moieties to interact with nucleic acid oligomers to aid in transport across cell membranes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PCT/US2018/054648 2017-10-05 2018-10-05 PROGRAMMABLE DENDRITIC MEDICINES Ceased WO2019071153A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP18792814.8A EP3691689A1 (en) 2017-10-05 2018-10-05 Programmable dendritic drugs
JP2020508523A JP7403744B2 (ja) 2017-10-05 2018-10-05 プログラマブルな樹枝状薬物
KR1020207006070A KR20200064059A (ko) 2017-10-05 2018-10-05 프로그램가능한 수지상 약물
US16/639,499 US12290571B2 (en) 2017-10-05 2018-10-05 Programmable dendritic drugs
CN201880056126.7A CN111093711A (zh) 2017-10-05 2018-10-05 可编程的树枝状药物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762568681P 2017-10-05 2017-10-05
US62/568,681 2017-10-05

Publications (1)

Publication Number Publication Date
WO2019071153A1 true WO2019071153A1 (en) 2019-04-11

Family

ID=63963607

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/054648 Ceased WO2019071153A1 (en) 2017-10-05 2018-10-05 PROGRAMMABLE DENDRITIC MEDICINES

Country Status (6)

Country Link
US (1) US12290571B2 (https=)
EP (1) EP3691689A1 (https=)
JP (1) JP7403744B2 (https=)
KR (1) KR20200064059A (https=)
CN (1) CN111093711A (https=)
WO (1) WO2019071153A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10844228B2 (en) 2018-03-30 2020-11-24 Becton, Dickinson And Company Water-soluble polymeric dyes having pendant chromophores
WO2021113651A3 (en) * 2019-12-04 2021-08-26 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery
CN115702007A (zh) * 2020-06-01 2023-02-14 Bik治疗公司 具有提高的药物递送和内化效率的药物偶联物
US11931418B2 (en) 2020-04-24 2024-03-19 Ashvattha Therapeutics, Inc. Methods of treating severe inflammation
US12180401B2 (en) 2021-04-07 2024-12-31 Becton, Dickinson And Company Water-soluble fluorescent polymeric dyes

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3019559A4 (en) 2013-08-22 2017-04-05 Sony Corporation Water soluble fluorescent or colored dyes and methods for their use
JP6806694B2 (ja) 2015-02-26 2021-01-06 ソニー株式会社 共役基を含む水溶性蛍光染料または有色染料
JP6982500B2 (ja) 2015-02-26 2021-12-17 ソニーグループ株式会社 フェニルエチニルナフタレン染料およびそれらの使用方法
US10865310B2 (en) 2015-05-11 2020-12-15 Sony Corporation Of America Ultra bright dimeric or polymeric dyes
AU2017240154B2 (en) 2016-04-01 2021-08-12 Sony Group Corporation Ultra bright dimeric or polymeric dyes
US11434377B2 (en) 2016-04-01 2022-09-06 Sony Corporation Ultra bright dimeric or polymeric dyes with rigid spacing groups
US9851359B2 (en) 2016-04-06 2017-12-26 Sony Corporation Of America Ultra bright dimeric or polymeric dyes with spacing linker groups
US11370922B2 (en) 2016-05-10 2022-06-28 Sony Corporation Ultra bright polymeric dyes with peptide backbones
WO2017197014A2 (en) 2016-05-10 2017-11-16 Sony Corporation Compositions comprising a polymeric dye and a cyclodextrin and uses thereof
KR102526802B1 (ko) 2016-05-11 2023-05-02 소니그룹주식회사 초고명도 이량체성 또는 중합체성 염료
WO2017214165A1 (en) 2016-06-06 2017-12-14 Sony Corporation Ionic polymers comprising fluorescent or colored reporter groups
JP7312929B2 (ja) 2016-07-29 2023-07-24 ソニーグループ株式会社 超明色二量体またはポリマー色素およびその調製のための方法
JP7551056B2 (ja) 2017-10-05 2024-09-17 ソニーグループ株式会社 プログラマブルなポリマー薬物
CN111836645A (zh) 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
EP3737419B1 (en) 2018-01-12 2024-04-10 Sony Group Corporation Phosphoalkyl polymers comprising biologically active compounds
CN111565756A (zh) 2018-01-12 2020-08-21 索尼公司 包含生物活性化合物的具有刚性间隔基团的聚合物
US12194104B2 (en) 2018-01-12 2025-01-14 Sony Group Corporation Phosphoalkyl ribose polymers comprising biologically active compounds
US11874280B2 (en) 2018-03-19 2024-01-16 Sony Group Corporation Use of divalent metals for enhancement of fluorescent signals
KR102864292B1 (ko) 2018-03-21 2025-09-26 소니그룹주식회사 링커 군을 갖는 중합체성 텐덤 염료
US12006438B2 (en) 2018-06-27 2024-06-11 Sony Group Corporation Polymeric dyes with linker groups comprising deoxyribose
EP3820944A1 (en) 2018-07-13 2021-05-19 Sony Corporation Polymeric dyes having a backbone comprising organophosphate units
US20220160887A1 (en) * 2019-04-11 2022-05-26 Sony Group Corporation Programmable polymeric drugs
WO2021062176A2 (en) 2019-09-26 2021-04-01 Sony Corporation Polymeric tandem dyes with linker groups
EP4038081A1 (en) 2019-09-30 2022-08-10 Sony Group Corporation Nucleotide probes
CN111521593B (zh) * 2020-05-12 2021-05-11 中国农业大学 一种基于水溶性苝酰亚胺衍生物的快速可视化检测方法
WO2022125564A1 (en) 2020-12-07 2022-06-16 Sony Group Corporation Spacing linker group design for brightness enhancement in dimeric or polymeric dyes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009132020A2 (en) * 2008-04-21 2009-10-29 The Regents Of The University Of California Selective high-affinity polydentate ligands and methods of making such
WO2015027176A1 (en) 2013-08-22 2015-02-26 Sony Corporation Water soluble fluorescent or colored dyes and methods for their use
WO2016138461A1 (en) 2015-02-26 2016-09-01 Sony Corporation Water soluble fluorescent or colored dyes comprising conjugating groups
WO2016183185A1 (en) 2015-05-11 2016-11-17 Sony Corporation Ultra bright dimeric or polymeric dyes

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450305A (en) 1982-10-25 1984-05-22 American Cyanamid Company Poly(ethyleneoxy)-substituted-9,10-bis(phenylethynyl)anthracenes
US4476229A (en) 1982-11-08 1984-10-09 Abbott Laboratories Substituted carboxyfluoresceins
SU1121931A1 (ru) 1983-01-10 1988-04-15 Институт Биологической Химии Ан Бсср Конъюгаты тиреоидных гормонов с альбумином дл выработки антител к тиреоидным гормонам у животных
EP0355864A3 (en) 1984-03-15 1991-09-18 Wako Pure Chemical Industries, Ltd. Method of quantitatively measuring an oxidative substance by using triphenyl methane type leuco compounds as coloring matter
JPH0665677B2 (ja) 1985-03-09 1994-08-24 三菱化成株式会社 リン脂質類似構造を有するジオ−ルおよびその製造方法
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
US5053054A (en) 1988-09-12 1991-10-01 Ortho Pharmaceutical Corporation Methods and reagents for staining intracellular components
US5318894A (en) 1990-01-30 1994-06-07 Miles Inc. Composition, device and method of assaying for peroxidatively active substances
US6365730B1 (en) 1990-06-19 2002-04-02 Gene Shears Pty. Limited DNA-Armed ribozymes and minizymes
JPH04282391A (ja) 1991-03-08 1992-10-07 Fujisawa Pharmaceut Co Ltd エタノールアミン誘導体およびその製造法
US5698391A (en) 1991-08-23 1997-12-16 Isis Pharmaceuticals, Inc. Methods for synthetic unrandomization of oligomer fragments
WO1993006482A1 (en) 1991-09-16 1993-04-01 Molecular Probes, Inc. Dimers of unsymmetrical cyanine dyes
EP1067134B1 (en) 1991-11-07 2004-07-28 Nanotronics, Inc. Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to-donor energy transfer system
WO1994024120A1 (en) 1993-04-13 1994-10-27 Naxcor Non-nucleosidic coumarin derivatives as polynucleotide-crosslinking agents
WO1995002700A1 (en) 1993-07-13 1995-01-26 Abbott Laboratories Fluorescent polymer labeled conjugates and intermediates
WO1995006731A2 (en) 1993-09-02 1995-03-09 Ribozyme Pharmaceuticals, Inc. Non-nucleotide containing enzymatic nucleic acid
US5886177A (en) 1994-01-11 1999-03-23 Isis Pharmaceuticals, Inc. Phosphate linked oligomers
US6171859B1 (en) 1994-03-30 2001-01-09 Mitokor Method of targeting conjugate molecules to mitochondria
US5994143A (en) 1996-02-01 1999-11-30 Abbott Laboratories Polymeric fluorophores enhanced by moieties providing a hydrophobic and conformationally restrictive microenvironment
US6218108B1 (en) 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
DE19633268A1 (de) 1996-08-19 1998-02-26 Hoechst Ag Polymere Gallensäure-Resorptionsinhibitoren mit gleichzeitiger Gallensäure-Adsorberwirkung
JP2001511128A (ja) 1997-01-28 2001-08-07 ファルマシア・アンド・アップジョン・カンパニー 水不溶性ポルフィリンの脂質錯体の凍結乾燥物
US6893868B2 (en) 1997-02-20 2005-05-17 Onco Immunin, Inc. Homo-doubly labeled compositions for the detection of enzyme activity in biological samples
US5986030A (en) 1997-04-15 1999-11-16 Nalco Chemical Company Fluorescent water soluble polymers
DE19717904A1 (de) 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
JP3078793B2 (ja) 1998-04-30 2000-08-21 株式会社分子バイオホトニクス研究所 ロタキサン構造を有する色素、ラベル化剤、およびラベル化方法
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6514700B1 (en) 1999-04-30 2003-02-04 Aclara Biosciences, Inc. Nucleic acid detection using degradation of a tagged sequence
US6627400B1 (en) 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US7037654B2 (en) 1999-04-30 2006-05-02 Aclara Biosciences, Inc. Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents
US20020142329A1 (en) 1999-04-30 2002-10-03 Aclara Biosciences, Inc. Compositions and methods employing cleavable electrophoretic tag reagents
AU5935300A (en) 1999-07-22 2001-02-13 Nalco Chemical Company Fluorescent water-soluble polymers
US6479650B1 (en) 1999-12-14 2002-11-12 Research Corporation Technologies, Inc. Fluorescent nucleoside analogs and combinatorial fluorophore arrays comprising same
AU2001245643A1 (en) 2000-03-14 2001-09-24 Genigma Corporation Biomarkers for the labeling, visual detection and quantification of biomolecules
JP2004515208A (ja) 2000-03-28 2004-05-27 ナノスフェアー インコーポレイテッド オリゴヌクレオチドを付着させたナノ粒子とその使用方法
US20040067498A1 (en) 2000-04-28 2004-04-08 Ahmed Chenna Detection of nucleic acid sequences by cleavage and separation of tag-containing structures
US6743640B2 (en) 2000-05-08 2004-06-01 Qtl Biosystems Llc Fluorescent polymer-QTL approach to biosensing
AU2001265252A1 (en) 2000-05-31 2001-12-11 The Johns-Hopkins University Biologically useful polyphosphates
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
JP2004508838A (ja) 2000-09-11 2004-03-25 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 組合せ蛍光エネルギー移動タグ及びそれらの使用
EP1319047B1 (en) 2000-09-19 2006-01-04 Li-Cor, Inc. Cyanine dyes
US6448407B1 (en) 2000-11-01 2002-09-10 Pe Corporation (Ny) Atropisomers of asymmetric xanthene fluorescent dyes and methods of DNA sequencing and fragment analysis
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
GB2372256A (en) 2001-02-14 2002-08-21 Kalibrant Ltd Detectable entity comprising a plurality of detectable units releasably connected together by stimulus-cleavable linkers for use in fluorescence detection
US6743905B2 (en) 2001-04-16 2004-06-01 Applera Corporation Mobility-modified nucleobase polymers and methods of using same
US8323903B2 (en) 2001-10-12 2012-12-04 Life Technologies Corporation Antibody complexes and methods for immunolabeling
JP3813890B2 (ja) 2002-03-22 2006-08-23 富士写真フイルム株式会社 ３層レジストプロセス用中間層材料組成物及びそれを用いたパターン形成方法
US7270956B2 (en) 2002-08-26 2007-09-18 The Regents Of The University Of California Methods and compositions for detection and analysis of polynucleotides using light harvesting multichromophores
US20040086914A1 (en) 2002-07-12 2004-05-06 Affymetrix, Inc. Nucleic acid labeling methods
US6806523B2 (en) * 2002-07-15 2004-10-19 Micron Technology, Inc. Magnetoresistive memory devices
AU2003262833A1 (en) 2002-08-23 2004-03-11 The Board Of Trustees Of The Leland Stanford Junior University Fluorescent glycosides and methods for their use
US20040138467A1 (en) 2002-11-26 2004-07-15 French Roger Harquail Aromatic and aromatic/heteroaromatic molecular structures with controllable electron conducting properties
US7759459B2 (en) 2003-01-10 2010-07-20 Albert Einstein College Of Medicine Of Yeshiva University Fluorescent assays for protein kinases
US7238792B2 (en) 2003-03-18 2007-07-03 Washington State University Research Foundation Foldable polymers as probes
US7172907B2 (en) 2003-03-21 2007-02-06 Ge Healthcare Bio-Sciences Corp. Cyanine dye labelling reagents with meso-substitution
ES2330115T3 (es) 2003-08-14 2009-12-04 Cellectis Composicion antibacteriana, mas particilarmente contra las bacterias gram-negativas, que comprende un peptido y un agente antibacteriano ventajosamente hidrofobo.
EP1689764B1 (en) 2003-11-19 2013-01-02 AlleLogic Biosciences Corporation Oligonucleotides labeled with a plurality of fluorophores
US20050123935A1 (en) 2003-12-09 2005-06-09 Richard Haugland Pyrenyloxysulfonic acid fluorescent agents
AU2005325262B2 (en) 2004-04-27 2011-08-11 Alnylam Pharmaceuticals, Inc. Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
US20060035302A1 (en) 2004-06-21 2006-02-16 Applera Corporation Kinase substrates with multiple phosphorylation sites
EP1781675B1 (en) 2004-08-13 2014-03-26 Epoch Biosciences, Inc. Phosphonate fluorescent dyes and conjugates
EP1789794A1 (en) 2004-09-14 2007-05-30 Applera Corporation, Applied Biosystems Group Multi-chromophoric quencher constructs for use in high sensitivity energy transfer probes
US8153706B2 (en) 2004-10-25 2012-04-10 Hewlett-Packard Development Company, L.P. Polymeric colorants having pigment and dye components and corresponding ink compositions
ATE364643T1 (de) 2004-11-09 2007-07-15 Ipagsa Ind Sl Thermisch reaktive, nah-infrarot absorbierende polymere und ihre verwendung in wärmeempfindlichen lithographischen druckplatten
EP2502946B1 (en) 2005-01-10 2017-10-04 The Regents of The University of California Cationic conjugated polymers suitable for strand-specific polynucleiotide detection in homogeneous and solid state assays
CA2599709A1 (en) 2005-03-09 2006-09-21 Cepheid Polar dyes
US8227621B2 (en) 2005-06-30 2012-07-24 Li-Cor, Inc. Cyanine dyes and methods of use
EP1928822B1 (en) 2005-09-26 2013-02-27 Life Technologies Corporation Violet laser excitable dyes and their method of use
US7888043B2 (en) 2005-11-18 2011-02-15 The United States Of America As Represented By The Department Of Health And Human Services, Centers For Disease Control And Prevention Modified cardiolipin and uses therefor
EP1961052B1 (en) 2005-12-12 2013-03-06 Basf Se Organic semiconductors and their manufacture
US20070148094A1 (en) 2005-12-22 2007-06-28 Uzgiris Egidijus E Polymeric imaging agents and medical imaging methods
JP5493117B2 (ja) 2006-02-15 2014-05-14 国立大学法人岐阜大学 オリゴヌクレオチド誘導体及びその利用
DK2029120T3 (da) 2006-04-13 2011-10-31 Midatech Ltd Nanopartikler indeholdende tre forskellige ligander til tilvejebringelse af immunresponser mod smitstoffer
WO2008021208A2 (en) 2006-08-12 2008-02-21 Stx Aprilis, Inc. Sensitizer dyes for photoacid generating systems using short visible wavelengths
CN101523631B (zh) 2006-10-12 2010-09-22 出光兴产株式会社 有机薄膜晶体管元件以及有机薄膜发光晶体管
WO2008076524A2 (en) 2006-10-27 2008-06-26 Life Technologies Corporation Fluorogenic ph sensitive dyes and their method of use
US8053588B2 (en) 2007-03-07 2011-11-08 Kabushiki Kaisha Toyota Chuo Kenkyusho Organosilane compound and organosilica obtained therefrom
PT2144633E (pt) 2007-04-23 2014-10-27 Deliversir Ltd Um sistema para a administração de agentes terapêuticos em células vivas e núcleos de células
US9156865B2 (en) 2007-04-23 2015-10-13 Deliversir Ltd System for delivering therapeutic agents into living cells and cells nuclei
US9556210B2 (en) 2007-04-23 2017-01-31 Sabag-Rfa Ltd. System for delivering therapeutic agents into living cells and cells nuclei
JP5518697B2 (ja) 2007-05-11 2014-06-11 ビーエーエスエフ ソシエタス・ヨーロピア 高分子色素
EP2014698A1 (en) 2007-07-12 2009-01-14 Crystax Pharmaceuticals S.L. Polymers and their use as fluorescent labels
TWI409280B (zh) 2007-07-31 2013-09-21 American Dye Source Inc 聚合物染料、塗覆層組合物及熱微影印刷板
GB2456298A (en) 2008-01-07 2009-07-15 Anthony Ian Newman Electroluminescent materials comprising oxidation resistant fluorenes
JP5467366B2 (ja) 2008-03-10 2014-04-09 国立大学法人 東京大学 非荷電性親水性ブロック及び側鎖の一部に疎水性基が導入されたカチオン性のポリアミノ酸ブロックを含んでなる共重合体、その使用
KR101041446B1 (ko) 2008-07-21 2011-06-14 부산대학교 산학협력단 공액고분자 2단계 ｆｒｅｔ 시스템 및 바이오센서
WO2010026957A1 (ja) 2008-09-03 2010-03-11 国立大学法人 富山大学 水溶性ロタキサン型蛍光色素および蛍光性有機分子
WO2010055789A1 (ja) 2008-11-14 2010-05-20 独立行政法人科学技術振興機構 オリゴヌクレオチド誘導体、ラベル化剤及びその利用
EP2366027B1 (en) 2008-11-20 2017-01-11 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Rapid fret-based diagnosis of bacterial pathogens
CN102317332B (zh) 2008-12-12 2014-04-30 马萨诸塞大学 两性离子聚合物
CN102791827B (zh) 2009-11-09 2016-11-16 华盛顿大学商业化中心 官能化发色聚合物点及其生物共轭体
US9400273B1 (en) 2009-12-09 2016-07-26 Life Technologies Corporation 7-hydroxycoumarin-based cell-tracking reagents
US9221759B2 (en) 2010-01-13 2015-12-29 Rutgers, The State University Of New Jersey Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency
WO2011113020A1 (en) 2010-03-11 2011-09-15 Glumetrics, Inc. Measurement devices and methods for measuring analyte concentration incorporating temperature and ph correction
US8349308B2 (en) 2010-03-26 2013-01-08 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
EP2577309B1 (en) 2010-05-25 2016-11-23 Carnegie Mellon University Targeted probes of cellular physiology
WO2012005310A1 (ja) 2010-07-08 2012-01-12 旭硝子株式会社 含フッ素芳香族化合物、有機半導体材料および有機薄膜デバイス
EP3345944B1 (en) 2010-09-22 2020-03-18 The Board of Regents of the University of Texas System Novel block copolymer and micelle compositions and methods of use thereof
CA2821411C (en) 2010-12-13 2020-02-25 Quiapeg Pharmaceuticals Ab Functionalized polymers
WO2012086857A1 (ko) 2010-12-21 2012-06-28 (주)파낙스이엠 광역학 진단 또는 치료를 위한 결합체 및 이의 제조방법
CN102174078A (zh) 2011-01-10 2011-09-07 中国药科大学 肿瘤细胞选择性穿膜肽的应用
EP2769226B1 (en) 2011-07-15 2017-05-24 Medtronic Minimed, Inc. Combinations of fluorphores and pyridinium boronic acid quenchers for use in analyte sensors
CA2845845A1 (en) 2011-08-31 2013-03-07 Mallinckrodt Llc Nanoparticle peg modification with h-phosphonates
US20130059343A1 (en) 2011-09-06 2013-03-07 Li-Cor, Inc. Nucleotide derivatives
US9085761B1 (en) 2012-06-14 2015-07-21 Affymetrix, Inc. Methods and compositions for amplification of nucleic acids
US9932578B2 (en) 2012-09-12 2018-04-03 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to P53 and methods of use thereof
US20150258217A1 (en) 2012-10-04 2015-09-17 The General Hospital Corporation Methods of Synthesizing and Using Peg-Like Fluorochromes
CN104918639B (zh) 2012-10-22 2018-01-26 萨拜格Rfa公司 用于将治疗剂递送到活细胞和细胞核中的系统
WO2014102803A1 (en) 2012-12-31 2014-07-03 Yeda Research And Development Co. Ltd. Molecular sensor and methods of use thereof
US9545447B2 (en) 2013-01-04 2017-01-17 The Texas A&M University System Polymer-drug systems
US9169256B2 (en) 2013-03-13 2015-10-27 Elitechgroup B.V. Artificial nucleic acids
US9714946B2 (en) 2013-03-14 2017-07-25 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
JP6606487B2 (ja) 2013-03-15 2019-11-13 ビセン メディカル， インコーポレイテッド ｉｎｖｉｔｒｏおよびｉｎｖｉｖｏイメージングおよび検出のための置換シラキサンテニウム赤色〜近赤外蛍光色素
WO2014147642A1 (en) 2013-03-19 2014-09-25 Council Of Scientific & Industrial Research Substituted fluoranthene-7-carbonitriles as fluorescent dyes for cell imaging applications
CN103319378B (zh) 2013-06-27 2015-06-10 中国科学院宁波材料技术与工程研究所 两性离子有机小分子太阳能电池阴极界面材料及其制法和用途
KR101572901B1 (ko) 2013-07-12 2015-12-15 부산대학교 산학협력단 2-단계 fret를 이용한 공액고분자 전해질 및 압타머 프로브 기반 표적 물질의 검출 방법 및 형광 센서
TWI603305B (zh) * 2013-09-27 2017-10-21 鴻海精密工業股份有限公司 顯示裝置、拼接式顯示器及顯示面板
US10406246B2 (en) 2013-10-17 2019-09-10 Deutsches Kresbsforschungszentrum Double-labeled probe for molecular imaging and use thereof
WO2015068697A1 (ja) 2013-11-11 2015-05-14 オリンパスメディカルシステムズ株式会社 処置システム
CN105829427A (zh) 2013-12-06 2016-08-03 蒙诺苏尔有限公司 用于水溶性膜的荧光示踪剂、相关方法和相关物品
CA2929972C (en) 2013-12-20 2018-07-24 F. Hoffmann-La Roche Ag Use of compounds comprising two or more hydrophobic domains and a hydrophilic domain comprising peg moieties for stabilization of a cell
US9689877B2 (en) 2014-01-16 2017-06-27 Sony Corporation Water soluble fluorescent or colored dyes and methods for their use
JP6374172B2 (ja) 2014-01-31 2018-08-15 富士フイルム株式会社 着色組成物、およびこれを用いた硬化膜、カラーフィルタ、パターン形成方法、カラーフィルタの製造方法、固体撮像素子、画像表示装置ならびに染料多量体
CN104072727A (zh) 2014-06-23 2014-10-01 华南理工大学 一种含磷脂酰胆碱基的2,7-芴的共轭聚合物及其制备方法与应用
MX2017004580A (es) 2014-10-10 2017-06-27 Pfizer Combinaciones de auristatina sinergica.
WO2016077625A1 (en) 2014-11-12 2016-05-19 Stayton Patrick S Stabilized polymeric carriers for therapeutic agent delivery
EP3218414A1 (en) 2014-11-14 2017-09-20 Angiochem Inc. Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
DK178808B1 (en) 2014-12-12 2017-02-13 Envision Energy Denmark Aps Floating wind turbine structure with reduced tower height and method for optimising the weight thereof
JP6982500B2 (ja) 2015-02-26 2021-12-17 ソニーグループ株式会社 フェニルエチニルナフタレン染料およびそれらの使用方法
US9758625B2 (en) 2015-03-12 2017-09-12 Becton, Dickinson And Company Polymeric BODIPY dyes and methods for using the same
US9670318B2 (en) 2015-05-28 2017-06-06 Miltenyi Biotec Gmbh Bright fluorochromes based on multimerization of fluorescent dyes
JP6997455B2 (ja) 2015-06-02 2022-01-17 ユニバーシティ・オブ・ワシントン 自立非汚染性ポリマー、それらの組成物、および関連モノマー
JP6817288B2 (ja) 2015-08-10 2021-01-20 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 新規な連結体及び生体分子と薬物との特異的共役におけるその使用
US9691615B2 (en) * 2015-08-28 2017-06-27 International Business Machines Corporation Chemoepitaxy-based directed self assembly process with tone inversion for unidirectional wiring
WO2017062271A2 (en) 2015-10-06 2017-04-13 Merck Sharp & Dohme Corp. Antibody drug conjugate for anti-inflammatory applications
HRP20240795T1 (hr) 2015-11-25 2024-09-13 Ligachem Biosciences Inc. Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima
WO2017094897A1 (ja) 2015-12-04 2017-06-08 全薬工業株式会社 血中滞留性を改善した抗ｉｌ－１７アプタマー
US9913992B2 (en) 2015-12-22 2018-03-13 Colgate-Palmolive Company Oral treatment device
JP2017124994A (ja) * 2016-01-15 2017-07-20 靖彦 中村 癌治療及び癌再発防止のための装置並びにポルフィリン類含有製剤
AU2017240154B2 (en) 2016-04-01 2021-08-12 Sony Group Corporation Ultra bright dimeric or polymeric dyes
US11434377B2 (en) 2016-04-01 2022-09-06 Sony Corporation Ultra bright dimeric or polymeric dyes with rigid spacing groups
US9851359B2 (en) 2016-04-06 2017-12-26 Sony Corporation Of America Ultra bright dimeric or polymeric dyes with spacing linker groups
WO2017197014A2 (en) 2016-05-10 2017-11-16 Sony Corporation Compositions comprising a polymeric dye and a cyclodextrin and uses thereof
US11370922B2 (en) 2016-05-10 2022-06-28 Sony Corporation Ultra bright polymeric dyes with peptide backbones
KR102526802B1 (ko) 2016-05-11 2023-05-02 소니그룹주식회사 초고명도 이량체성 또는 중합체성 염료
WO2017214165A1 (en) 2016-06-06 2017-12-14 Sony Corporation Ionic polymers comprising fluorescent or colored reporter groups
JP7312929B2 (ja) 2016-07-29 2023-07-24 ソニーグループ株式会社 超明色二量体またはポリマー色素およびその調製のための方法
EP3507603B1 (en) 2016-09-01 2024-03-06 Life Technologies Corporation Compositions and methods for enhanced fluorescence
GB2554666B (en) 2016-09-30 2019-12-18 Sumitomo Chemical Co Composite Particle
CN106589005B (zh) 2016-11-01 2019-08-06 北京擎科生物科技有限公司 一种荧光信号放大探针中间体、荧光探针及其制备方法
CA3054609A1 (en) 2017-02-27 2018-08-30 Ivanti, Inc. Systems and methods for role-based computer security configurations
US12398104B2 (en) 2017-04-27 2025-08-26 The Procter & Gamble Company Odorless thiols for permanent waving, straightening and depilatory applications
WO2019010414A1 (en) 2017-07-07 2019-01-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Fatty acid derivatives and their use
JP7551056B2 (ja) 2017-10-05 2024-09-17 ソニーグループ株式会社 プログラマブルなポリマー薬物
CN111836645A (zh) 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
WO2019118714A1 (en) 2017-12-13 2019-06-20 Sony Corporation Ionic polymers comprising biologically active compounds
EP3727463A1 (en) 2017-12-21 2020-10-28 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
CN111565756A (zh) 2018-01-12 2020-08-21 索尼公司 包含生物活性化合物的具有刚性间隔基团的聚合物
EP3737419B1 (en) 2018-01-12 2024-04-10 Sony Group Corporation Phosphoalkyl polymers comprising biologically active compounds
US12194104B2 (en) 2018-01-12 2025-01-14 Sony Group Corporation Phosphoalkyl ribose polymers comprising biologically active compounds
US11874280B2 (en) 2018-03-19 2024-01-16 Sony Group Corporation Use of divalent metals for enhancement of fluorescent signals
KR102864292B1 (ko) 2018-03-21 2025-09-26 소니그룹주식회사 링커 군을 갖는 중합체성 텐덤 염료
GB201807815D0 (en) 2018-05-14 2018-06-27 Hypha Discovery Ltd Hydroxylation techniques
US12006438B2 (en) 2018-06-27 2024-06-11 Sony Group Corporation Polymeric dyes with linker groups comprising deoxyribose
EP3820944A1 (en) 2018-07-13 2021-05-19 Sony Corporation Polymeric dyes having a backbone comprising organophosphate units
EP3952918A1 (en) 2019-04-11 2022-02-16 Sony Group Corporation Programmable polymeric drugs
WO2020210692A1 (en) 2019-04-11 2020-10-15 Sony Corporation Programmable polymeric drugs
WO2020219959A1 (en) 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anti-cd45 antibody drug conjugates and uses thereof
WO2021062176A2 (en) 2019-09-26 2021-04-01 Sony Corporation Polymeric tandem dyes with linker groups
EP4038081A1 (en) 2019-09-30 2022-08-10 Sony Group Corporation Nucleotide probes
EP4251764A1 (en) 2020-11-25 2023-10-04 Sony Group Corporation Polymer dyes
WO2022125564A1 (en) 2020-12-07 2022-06-16 Sony Group Corporation Spacing linker group design for brightness enhancement in dimeric or polymeric dyes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009132020A2 (en) * 2008-04-21 2009-10-29 The Regents Of The University Of California Selective high-affinity polydentate ligands and methods of making such
WO2015027176A1 (en) 2013-08-22 2015-02-26 Sony Corporation Water soluble fluorescent or colored dyes and methods for their use
WO2016138461A1 (en) 2015-02-26 2016-09-01 Sony Corporation Water soluble fluorescent or colored dyes comprising conjugating groups
WO2016183185A1 (en) 2015-05-11 2016-11-17 Sony Corporation Ultra bright dimeric or polymeric dyes

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", December 2000, WILEY
"Pharmaceutical Dosage Forms and Drug Delivery Systems", 1999, LIPPINCOTT WILLIAMS & WILKINS
"Pharmaceutical Dosage Forms", 1980, MARCEL DECKER
"Remington: The Science and Practice of Pharmacy", 1995, MACK PUBLISHING COMPANY
GREEN, T.W.; P.G.M. WUTZ: "Protective Groups in Organic Synthesis", 1999, WILEY
HOOVER, JOHN E.: "Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING CO.
JAIN NARESHKUMAR ET AL: "Current ADC Linker Chemistry", PHARMACEUTICAL RESEARCH, SPRINGER NEW YORK LLC, US, vol. 32, no. 11, 11 March 2015 (2015-03-11), pages 3526 - 3540, XP035553874, ISSN: 0724-8741, [retrieved on 20150311], DOI: 10.1007/S11095-015-1657-7 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10844228B2 (en) 2018-03-30 2020-11-24 Becton, Dickinson And Company Water-soluble polymeric dyes having pendant chromophores
US11214688B2 (en) 2018-03-30 2022-01-04 Becton, Dickinson And Company Water-soluble polymeric dyes having pendant chromophores
US11702547B2 (en) 2018-03-30 2023-07-18 Becton, Dickinson And Company Water-soluble polymeric dyes having pendant chromophores
US12497516B2 (en) 2018-03-30 2025-12-16 Becton, Dickinson And Company Water-soluble polymeric dyes having pendant chromophores
WO2021113651A3 (en) * 2019-12-04 2021-08-26 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery
US11931418B2 (en) 2020-04-24 2024-03-19 Ashvattha Therapeutics, Inc. Methods of treating severe inflammation
CN115702007A (zh) * 2020-06-01 2023-02-14 Bik治疗公司 具有提高的药物递送和内化效率的药物偶联物
JP2023534377A (ja) * 2020-06-01 2023-08-09 ビーアイケー セラピューティクス インク． 薬物伝達と内在化効率が強化された薬物複合体
AU2021284541B2 (en) * 2020-06-01 2025-03-06 Bik Therapeutics Inc. Drug conjugate having enhanced drug delivery and internalization efficiency
JP7646705B2 (ja) 2020-06-01 2025-03-17 ビーアイケー セラピューティクス インク． 薬物伝達と内在化効率が強化された薬物複合体
JP2025066706A (ja) * 2020-06-01 2025-04-23 ビーアイケー セラピューティクス インク． 薬物伝達と内在化効率が強化された薬物複合体
US12180401B2 (en) 2021-04-07 2024-12-31 Becton, Dickinson And Company Water-soluble fluorescent polymeric dyes

Also Published As

Publication number Publication date
JP7403744B2 (ja) 2023-12-25
US12290571B2 (en) 2025-05-06
US20200222554A1 (en) 2020-07-16
CN111093711A (zh) 2020-05-01
EP3691689A1 (en) 2020-08-12
JP2020536845A (ja) 2020-12-17
KR20200064059A (ko) 2020-06-05

Similar Documents

Publication Publication Date Title
US12290571B2 (en) Programmable dendritic drugs
EP3737418B1 (en) Polymers with rigid spacing groups comprising biologically active compounds
US12194104B2 (en) Phosphoalkyl ribose polymers comprising biologically active compounds
EP3737419B1 (en) Phosphoalkyl polymers comprising biologically active compounds
US11931419B2 (en) Programmable polymeric drugs
KR102908167B1 (ko) 프로그램가능한 중합체성 약물
US20250161467A1 (en) Ionic polymers comprising biologically active compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18792814

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020508523

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018792814

Country of ref document: EP

Effective date: 20200506

WWC Wipo information: continuation of processing after refusal or withdrawal

Ref document number: 1020207006070

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 16639499

Country of ref document: US